Literature DB >> 11086664

The effects of serotonin (5-HT3) receptor antagonists on gastric tachyarrhythmia and the symptoms of motion sickness.

M E Levine1, J C Chillas, R M Stern, G W Knox.   

Abstract

BACKGROUND: The purpose of this study was to determine the effects of the serotonin (5-HT3) receptor-antagonist antiemetics ondansetron and granisetron on the development of gastric tachyarrhythmia, nausea, and other symptoms of motion sickness.
METHODS: In a double-blind, counterbalanced, repeated measures design, 12 motion sickness susceptible college students participated in 3 sessions with an intersession interval of 1 wk. Participants received either 8 mg of ondansetron, 2 mg of granisetron, or placebo 1 h before exposure to a rotating optokinetic drum. Electrogastrograms (EGGs) were recorded during a 6-min baseline period and a subsequent 16-min drum rotation period. Subjective symptoms of motion sickness (SSMS) were obtained every 3 min during drum rotation.
RESULTS: During drum rotation, gastric tachyarrhythmia increased significantly more during the placebo condition than during either of the serotonin (5-HT3) receptor antagonist conditions. However, maximum SSMS scores were not different among conditions.
CONCLUSIONS: The serotonin (5-HT3) receptor antagonists inhibited the development of tachyarrhythmia, but did not prevent the development of nausea and other symptoms of motion sickness. The antiemetics ondansetron and granisetron may act as gastric anti-dysrhythmics, but their ability to arrest the development of gastric tachyarrhythmia was not sufficient for the prevention of nausea.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11086664

Source DB:  PubMed          Journal:  Aviat Space Environ Med        ISSN: 0095-6562


  9 in total

1.  Gastric myoelectrical and autonomic cardiac reactivity to laboratory stressors.

Authors:  P J Gianaros; K S Quigley; J T Mordkoff; R M Stern
Journal:  Psychophysiology       Date:  2001-07       Impact factor: 4.016

Review 2.  Sickness and satiety: physiological mechanisms underlying perceptions of nausea and stomach fullness.

Authors:  Max E Levine
Journal:  Curr Gastroenterol Rep       Date:  2005-08

3.  Reduced normogastric electrical activity associated with emesis: a telemetric study in ferrets.

Authors:  Nathalie Percie du Sert; Kit M Chu; Man K Wai; John A Rudd; Paul Lr Andrews
Journal:  World J Gastroenterol       Date:  2009-12-28       Impact factor: 5.742

4.  Relationship of gastric myoelectrical and cardiac parasympathetic activity to chemotherapy-induced nausea.

Authors:  P J Gianaros; R M Stern; G R Morrow; J T Hickok
Journal:  J Psychosom Res       Date:  2001-05       Impact factor: 3.006

5.  Enhanced perceptions of control and predictability reduce motion-induced nausea and gastric dysrhythmia.

Authors:  Max E Levine; Robert M Stern; Kenneth L Koch
Journal:  Exp Brain Res       Date:  2014-04-20       Impact factor: 1.972

6.  Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation.

Authors:  D Bolognini; E M Rock; N L Cluny; M G Cascio; C L Limebeer; M Duncan; C G Stott; F A Javid; L A Parker; R G Pertwee
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

7.  Envelope statistics of self-motion signals experienced by human subjects during everyday activities: Implications for vestibular processing.

Authors:  Jérome Carriot; Mohsen Jamali; Kathleen E Cullen; Maurice J Chacron
Journal:  PLoS One       Date:  2017-06-02       Impact factor: 3.240

8.  Clinical Evaluation of the Use of Ginger Extract in the Preventive Management of Motion Sickness.

Authors:  Carlos Pereira Nunes; Claudio de Campos Rodrigues; Carlos Alfredo Franco Cardoso; Natasha Cytrynbaum; Renato Kaufman; Helio Rzetelna; Gerson Goldwasser; Alessandra Santos; Lisa Oliveira; Mauro Geller
Journal:  Curr Ther Res Clin Exp       Date:  2020-06-15

9.  Motion sickness: more than nausea and vomiting.

Authors:  James R Lackner
Journal:  Exp Brain Res       Date:  2014-06-25       Impact factor: 1.972

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.